PLANO, Texas / Feb 19, 2025 / Business Wire / Spok Holdings, Inc. (NASDAQ: SPOK), a global leader in healthcare communications, today announced it will release its fourth quarter and full year 2024 operating results on Wednesday, February 26, 2025, after the close of the U.S. financial markets.
Management will host a conference call and webcast to discuss these financial results on Wednesday, February 26, 2025, at 5:00 p.m. ET. The presentation is open to all interested parties and may include forward-looking information.
Conference Call Details
Date/Time | Wednesday, February 26, 2025, at 5:00 p.m. ET | |||
Webcast: | Q4 2024 Earnings Results (webcast-eqs.com) | |||
U.S. Toll-Free Dial In: | 877-407-0890 | |||
International Dial In: | +1-201-389-0918 |
To access the call, please dial in approximately ten minutes before the start of the call. For those unable to join the live call, an OnDemand version of the webcast will be available following the call under the URL link and on the investor relations website.
About Spok
Spok Holdings, Inc. (NASDAQ: SPOK), headquartered in Plano, Texas, is proud to be a global leader in healthcare communications. We deliver clinical information to care teams when and where it matters most to improve patient outcomes. Top hospitals rely on the Spok Care Connect® platform to enhance workflows for clinicians and support administrative compliance. Our customers send over 70 million messages each month through their Spok® solutions. Spok enables smarter, faster clinical communication.
Spok is a trademark of Spok Holdings, Inc. Spok Care Connect and Spok Mobile are trademarks of Spok, Inc.
Last Trade: | US$18.41 |
Daily Change: | -0.02 -0.11 |
Daily Volume: | 334,610 |
Market Cap: | US$379.060M |
July 30, 2025 April 30, 2025 February 26, 2025 October 30, 2024 July 24, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load